Blue Cross Blue Shield of Minnesota Medical Policy

 
 

Medical Policy:
IV-28-004
Topic:
Gastric Electrical Stimulation
Section:
Surgery
Effective Date:
April 27, 2020
Issued Date:
May 3, 2021
Last Revision Date:
April 2020
Annual Review:
April 2021
 
 

This policy version was replaced May 2, 2022. To find the newest version, go to https://www.bluecrossmn.com/providers/medical-policy-and-utilization-management, read and accept the Blue Cross Medical Policy Statement, then select “Blue Cross and Blue Shield of Minnesota Medical Policies.” This will bring up the Medical Policy search screen. Enter the policy number without the version number (last 3 digits).

Gastric electrical stimulation (GES) is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastroparesis of diabetic, idiopathic, or postsurgical etiology. GES has also been investigated as a treatment of obesity. The device may be referred to as a gastric pacemaker.

A gastric electrical stimulator system called Enterra™ Therapy System (Medtronic) was approved by the U.S. Food and Drug Administration (FDA) through the humanitarian device exemption process for the treatment of gastroparesis. The GES system consists of 4 components: the implanted pulse generator, 2 unipolar intramuscular stomach leads, the stimulator programmer, and the memory cartridge. The intramuscular stomach leads are implanted either laparoscopically or during a laparotomy and are connected to the pulse generator, which is implanted in a subcutaneous pocket. The programmer sets the stimulation parameters, which are typically set at an “on” time of 0.1 second alternating with an “off” time of 5.0 seconds. Currently, no GES devices have been approved by the FDA for the treatment of obesity.

This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Policy Position Coverage is subject to the specific terms of the member's benefit plan.

I.   Gastric electrical stimulation using an FDA-approved device may be considered MEDICALLY NECESSARY AND APPROPRIATE in the treatment of chronic intractable nausea and vomiting secondary to severe gastroparesis of diabetic or idiopathic etiology when ALL of the following criteria are met:

  • Symptomatic gastroparesis ≥ one year, confirmed by an initial gastric emptying test; AND
  • Previous dietary modification in consultation with a dietitian; AND
  • ONE of the following:
    • Failed at least TWO drug classes from EACH of the following:
      1. Antiemetics (e.g. antihistamines [e.g. diphenhydramine], serotonin receptor agonists [e.g. ondonsetron], dopamine receptor antagonists [e.g. prochlorperazine]); AND
      2. Prokinetics (e.g. dopamine receptor antagonists [e.g. metoclopramide], macrolide antibiotics [e.g. erythromycin]); OR
    • Documented intolerance, FDA labeled contraindication, or hypersensitivity to at least TWO drug classes from EACH of the following:
      1. Antiemetics (e.g. antihistamines [e.g. diphenhydramine], serotonin receptor agonists [e.g. ondonsetron], dopamine receptor antagonists [e.g. prochlorperazine]); AND
      2. Prokinetics (e.g. dopamine receptor antagonists [e.g. metoclopramide], macrolide antibiotics [e.g. erythromycin]); AND
  • In patients with diabetes, failure to improve despite optimization of glycemic control.

II.  Gastric electrical stimulation is considered EXPERIMENTAL/INVESTIGATIVE for all other indications due to a lack of clinical evidence demonstrating an impact on improved health outcomes, including but not limited to the treatment of:

  • Obesity,
  • Diabetes mellitus in persons without gastroparesis.
43647 43648 43659 43881 43882 43999 64590 64595 95980 95981 95982 L8680 L8685 L8686 L8687 L8688





Denial Statements

No additional statements.



Links





Blue Cross and Blue Shield of Minnesota medical policies apply generally to all Blue Cross and Blue Plus plans and products. Benefit plans vary in coverage and some plans may not provide coverage for certain services addressed in the medical policies. When determining coverage, reference the member’s specific benefit plan, including exclusions and limitations.

Medicaid products may provide different coverage for certain services, which may be addressed in different policies. For Minnesota Health Care Program (MHCP) policies, please consult the MHCP Provider Manual website.

Medicare products may provide different coverage for certain services, which may be addressed in different policies. For Medicare National Coverage Determinations (NCD), Local Coverage Determinations (LCD), and/or Local Coverage Articles, please consult CMS, National Government Services, or CGS websites. 

Note that services with specific coverage criteria may be reviewed retrospectively to determine if criteria are being met. Retrospective denial of claims may result if criteria are not met.

Blue Cross and Blue Shield of Minnesota reserves the right to revise, update and/or add to its medical policies at any time without notice. Codes listed on this policy are included for informational purposes only and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. 

These guidelines are the proprietary information of Blue Cross and Blue Shield of Minnesota. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.

Acknowledgements:

CPT® codes copyright American Medical Association® 2022. All rights reserved.

CDT codes copyright American Dental Association® 2022. All rights reserved.